Literature DB >> 19326101

Antagonism by haloperidol and its metabolites of mechanical hypersensitivity induced by intraplantar capsaicin in mice: role of sigma-1 receptors.

José M Entrena1, Enrique J Cobos, Francisco R Nieto, Cruz M Cendán, José M Baeyens, Esperanza Del Pozo.   

Abstract

RATIONALE: We evaluated the effects of haloperidol and its metabolites on capsaicin-induced mechanical hypersensitivity (allodynia) and on nociceptive pain induced by punctate mechanical stimuli in mice.
RESULTS: Subcutaneous administration of haloperidol or its metabolites I or II (reduced haloperidol) dose-dependently reversed capsaicin-induced (1 microg, intraplantar) mechanical hypersensitivity of the hind paw (stimulated with a nonpainful, 0.5-g force, punctate stimulus). The order of potency of these drugs to induce antiallodynic effects was the order of their affinity for brain sigma-1 (sigma(1)) receptor ([(3)H](+)-pentazocine-labeled). Antiallodynic activity of haloperidol and its metabolites was dose-dependently prevented by the selective sigma(1) receptor agonist PRE-084, but not by naloxone. These results suggest the involvement of sigma(1) receptors, but discard any role of the endogenous opioid system, on the antiallodynic effects. Dopamine receptor antagonism also appears unlikely to be involved in these effects, since the D(2)/D(3) receptor antagonist (-)-sulpiride, which had no affinity for sigma(1) receptors, showed no antiallodynic effect. None of these drugs modified hind-paw withdrawal after a painful (4 g force) punctate mechanical stimulus in noncapsaicin-sensitized animals. As expected, the control drug gabapentin showed antiallodynic but not antinociceptive activity, whereas clonidine exhibited both activities and rofecoxib, used as negative control, showed neither.
CONCLUSION: These results show that haloperidol and its metabolites I and II produce antiallodynic but not antinociceptive effects against punctate mechanical stimuli and suggest that their antiallodynic effect may be due to blockade of sigma(1) receptors but not to dopamine receptor antagonism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19326101      PMCID: PMC2695546          DOI: 10.1007/s00213-009-1513-8

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  60 in total

1.  In vivo evaluation of (+)-MR200 as a new selective sigma ligand modulating MOP, DOP and KOP supraspinal analgesia.

Authors:  Agostino Marrazzo; Carmela Parenti; Valentina Scavo; Simone Ronsisvalle; Giovanna Maria Scoto; Giuseppe Ronsisvalle
Journal:  Life Sci       Date:  2005-12-01       Impact factor: 5.037

Review 2.  Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders.

Authors:  G Debonnel; C de Montigny
Journal:  Life Sci       Date:  1996       Impact factor: 5.037

3.  Intrathecal treatment with sigma1 receptor antagonists reduces formalin-induced phosphorylation of NMDA receptor subunit 1 and the second phase of formalin test in mice.

Authors:  Hyun-Woo Kim; Young-Bae Kwon; Dae-Hyun Roh; Seo-Yeon Yoon; Ho-Jae Han; Kee-Won Kim; Alvin J Beitz; Jang-Hern Lee
Journal:  Br J Pharmacol       Date:  2006-05-08       Impact factor: 8.739

4.  Formalin-induced pain is reduced in sigma(1) receptor knockout mice.

Authors:  Cruz Miguel Cendán; José Miguel Pujalte; Enrique Portillo-Salido; Lluís Montoliu; José M Baeyens
Journal:  Eur J Pharmacol       Date:  2005-03-21       Impact factor: 4.432

5.  Comparison of antinociceptive actions of standard analgesics in attenuating capsaicin and nerve-injury-induced mechanical hypersensitivity.

Authors:  S K Joshi; G Hernandez; J P Mikusa; C Z Zhu; C Zhong; A Salyers; C T Wismer; P Chandran; M W Decker; P Honore
Journal:  Neuroscience       Date:  2006-09-08       Impact factor: 3.590

6.  Characterization of haloperidol and trifluperidol as subtype-selective N-methyl-D-aspartate (NMDA) receptor antagonists using [3H]TCP and [3H]ifenprodil binding in rat brain membranes.

Authors:  L L Coughenour; J J Cordon
Journal:  J Pharmacol Exp Ther       Date:  1997-02       Impact factor: 4.030

7.  Distinct modulatory roles of sigma receptor subtypes on glutamatergic responses in the dorsal hippocampus.

Authors:  Jordanna E Bermack; Guy Debonnel
Journal:  Synapse       Date:  2005-01       Impact factor: 2.562

8.  The cyclooxygenase-2 inhibitor GW406381X [2-(4-ethoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-pyrazolo[1,5-b]pyridazine] is effective in animal models of neuropathic pain and central sensitization.

Authors:  Sharon Bingham; Paul J Beswick; Chas Bountra; Terry Brown; Ian B Campbell; Iain P Chessell; Nick Clayton; Sue D Collins; Philip T Davey; Helen Goodland; Norman Gray; Claudine Haslam; Jonathan P Hatcher; A Jacqueline Hunter; Fiona Lucas; Graham Murkitt; Alan Naylor; Elizabeth Pickup; Becky Sargent; Scott G Summerfield; Alexander Stevens; Sharon C Stratton; Joanne Wiseman
Journal:  J Pharmacol Exp Ther       Date:  2004-11-30       Impact factor: 4.030

9.  Antinociceptive effects of haloperidol and its metabolites in the formalin test in mice.

Authors:  Cruz M Cendán; José M Pujalte; Enrique Portillo-Salido; José M Baeyens
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

10.  Neuroleptics antagonize nalbuphine antianalgesia.

Authors:  Robert W Gear; Janice S Lee; Christine Miaskowski; Newton C Gordon; Steven M Paul; Jon D Levine
Journal:  J Pain       Date:  2006-03       Impact factor: 5.820

View more
  14 in total

1.  Pharmacological properties of S1RA, a new sigma-1 receptor antagonist that inhibits neuropathic pain and activity-induced spinal sensitization.

Authors:  L Romero; D Zamanillo; X Nadal; R Sánchez-Arroyos; I Rivera-Arconada; A Dordal; A Montero; A Muro; A Bura; C Segalés; M Laloya; E Hernández; E Portillo-Salido; M Escriche; X Codony; G Encina; J Burgueño; M Merlos; J M Baeyens; J Giraldo; J A López-García; R Maldonado; C R Plata-Salamán; J M Vela
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

2.  Safety, tolerability and pharmacokinetics of single and multiple doses of a novel sigma-1 receptor antagonist in three randomized phase I studies.

Authors:  Montserrat Abadias; Marisol Escriche; Anna Vaqué; Mariano Sust; Gregorio Encina
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

3.  Sigma-1 receptors control immune-driven peripheral opioid analgesia during inflammation in mice.

Authors:  Miguel A Tejada; Angeles Montilla-García; Shane J Cronin; Domagoj Cikes; Cristina Sánchez-Fernández; Rafael González-Cano; M Carmen Ruiz-Cantero; Josef M Penninger; José M Vela; José M Baeyens; Enrique J Cobos
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-17       Impact factor: 11.205

Review 4.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

5.  Sigma-1 receptor inhibition reverses acute inflammatory hyperalgesia in mice: role of peripheral sigma-1 receptors.

Authors:  M A Tejada; A Montilla-García; C Sánchez-Fernández; J M Entrena; G Perazzoli; J M Baeyens; E J Cobos
Journal:  Psychopharmacology (Berl)       Date:  2014-03-18       Impact factor: 4.530

Review 6.  The role of antipsychotics in the management of fibromyalgia.

Authors:  Elena P Calandre; Fernando Rico-Villademoros
Journal:  CNS Drugs       Date:  2012-02-01       Impact factor: 5.749

7.  The Antinociceptive Effect of Sigma-1 Receptor Antagonist, BD1047, in a Capsaicin Induced Headache Model in Rats.

Authors:  Young Bae Kwon; Young Chan Jeong; Jung Kee Kwon; Ji Seon Son; Kee Won Kim
Journal:  Korean J Physiol Pharmacol       Date:  2009-12-31       Impact factor: 2.016

8.  The use of very-low-dose methadone for palliative pain control and the prevention of opioid hyperalgesia.

Authors:  Shelley R Salpeter; Jacob S Buckley; Eduardo Bruera
Journal:  J Palliat Med       Date:  2013-04-04       Impact factor: 2.947

9.  The selective sigma-1 receptor antagonist E-52862 attenuates neuropathic pain of different aetiology in rats.

Authors:  Georgia Gris; Enrique Portillo-Salido; Bertrand Aubel; Yassine Darbaky; Kristof Deseure; José Miguel Vela; Manuel Merlos; Daniel Zamanillo
Journal:  Sci Rep       Date:  2016-04-18       Impact factor: 4.379

10.  Genetic inactivation and pharmacological blockade of sigma-1 receptors prevent paclitaxel-induced sensory-nerve mitochondrial abnormalities and neuropathic pain in mice.

Authors:  Francisco R Nieto; Cruz M Cendán; Francisco J Cañizares; María A Cubero; José M Vela; Eduardo Fernández-Segura; José M Baeyens
Journal:  Mol Pain       Date:  2014-02-11       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.